These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 27646564)

  • 1. RET kinase inhibitors: a review of recent patents (2012-2015).
    Mologni L; Gambacorti-Passerini C; Goekjian P; Scapozza L
    Expert Opin Ther Pat; 2017 Jan; 27(1):91-99. PubMed ID: 27646564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of Tyrosine Kinase Inhibitors for Treatment of Medullary Thyroid Carcinoma.
    Dadu R; Hu MN; Grubbs EG; Gagel RF
    Recent Results Cancer Res; 2015; 204():227-49. PubMed ID: 26494392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers.
    Roskoski R; Sadeghi-Nejad A
    Pharmacol Res; 2018 Feb; 128():1-17. PubMed ID: 29284153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An updated patent review of rearranged during transfection (RET) kinase inhibitors (2016-present).
    Acharya B; Frett B
    Expert Opin Ther Pat; 2022 Oct; 32(10):1067-1077. PubMed ID: 36198171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting RET for thyroid cancer therapy.
    Lanzi C; Cassinelli G; Nicolini V; Zunino F
    Biochem Pharmacol; 2009 Feb; 77(3):297-309. PubMed ID: 19028457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Precision Targeted Therapy with BLU-667 for
    Subbiah V; Gainor JF; Rahal R; Brubaker JD; Kim JL; Maynard M; Hu W; Cao Q; Sheets MP; Wilson D; Wilson KJ; DiPietro L; Fleming P; Palmer M; Hu MI; Wirth L; Brose MS; Ou SI; Taylor M; Garralda E; Miller S; Wolf B; Lengauer C; Guzi T; Evans EK
    Cancer Discov; 2018 Jul; 8(7):836-849. PubMed ID: 29657135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RET fusions in solid tumors.
    Li AY; McCusker MG; Russo A; Scilla KA; Gittens A; Arensmeyer K; Mehra R; Adamo V; Rolfo C
    Cancer Treat Rev; 2019 Dec; 81():101911. PubMed ID: 31715421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcriptional targeting of oncogene addiction in medullary thyroid cancer.
    Valenciaga A; Saji M; Yu L; Zhang X; Bumrah C; Yilmaz AS; Knippler CM; Miles W; Giordano TJ; Cote GJ; Ringel MD
    JCI Insight; 2018 Aug; 3(16):. PubMed ID: 30135308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RET inhibition: implications in cancer therapy.
    Borrello MG; Ardini E; Locati LD; Greco A; Licitra L; Pierotti MA
    Expert Opin Ther Targets; 2013 Apr; 17(4):403-19. PubMed ID: 23461584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer.
    De Falco V; Carlomagno F; Li HY; Santoro M
    Best Pract Res Clin Endocrinol Metab; 2017 Jun; 31(3):307-318. PubMed ID: 28911727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective RET kinase inhibition for patients with RET-altered cancers.
    Subbiah V; Velcheti V; Tuch BB; Ebata K; Busaidy NL; Cabanillas ME; Wirth LJ; Stock S; Smith S; Lauriault V; Corsi-Travali S; Henry D; Burkard M; Hamor R; Bouhana K; Winski S; Wallace RD; Hartley D; Rhodes S; Reddy M; Brandhuber BJ; Andrews S; Rothenberg SM; Drilon A
    Ann Oncol; 2018 Aug; 29(8):1869-1876. PubMed ID: 29912274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors.
    La Pietra V; Sartini S; Botta L; Antonelli A; Ferrari SM; Fallahi P; Moriconi A; Coviello V; Quattrini L; Ke YY; Hsing-Pang H; Da Settimo F; Novellino E; La Motta C; Marinelli L
    Eur J Med Chem; 2018 Apr; 150():491-505. PubMed ID: 29549836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.
    De Falco V; Buonocore P; Muthu M; Torregrossa L; Basolo F; Billaud M; Gozgit JM; Carlomagno F; Santoro M
    J Clin Endocrinol Metab; 2013 May; 98(5):E811-9. PubMed ID: 23526464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted therapy: a new hope for thyroid carcinomas.
    Perri F; Pezzullo L; Chiofalo MG; Lastoria S; Di Gennaro F; Scarpati GD; Caponigro F
    Crit Rev Oncol Hematol; 2015 Apr; 94(1):55-63. PubMed ID: 25465739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting RET receptor tyrosine kinase activation in cancer.
    Phay JE; Shah MH
    Clin Cancer Res; 2010 Dec; 16(24):5936-41. PubMed ID: 20930041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer.
    Meng S; Wu H; Wang J; Qiu Q
    Mol Inform; 2016 Oct; 35(10):495-505. PubMed ID: 27712045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer.
    Krajewska J; Olczyk T; Jarzab B
    Expert Rev Clin Pharmacol; 2016; 9(1):69-79. PubMed ID: 26536165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progress and potential impact of RET kinase targeting in cancer.
    Mulligan LM
    Expert Rev Proteomics; 2016 Jul; 13(7):631-3. PubMed ID: 27337654
    [No Abstract]   [Full Text] [Related]  

  • 19. Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase.
    Mologni L; Redaelli S; Morandi A; Plaza-Menacho I; Gambacorti-Passerini C
    Mol Cell Endocrinol; 2013 Sep; 377(1-2):1-6. PubMed ID: 23811235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High Affinity Pharmacological Profiling of Dual Inhibitors Targeting RET and VEGFR2 in Inhibition of Kinase and Angiogeneis Events in Medullary Thyroid Carcinoma.
    Dunna NR; Kandula V; Girdhar A; Pudutha A; Hussain T; Bandaru S; Nayarisseri A
    Asian Pac J Cancer Prev; 2015; 16(16):7089-95. PubMed ID: 26514495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.